On September 1, MiniMed (NASDAQ:MMED) reported its first full quarter as a stand-alone public company, and the numbers suggest the split from Medtronic is already paying off. Revenue jumped 15.8% to $843 million, and management raised its full-year growth outlook just months after the IPO roadshow. The catalyst is simple. A new pump finally shipped, and patients are showing up for it.
Every New Product Is Landing
The headline number came from the US business, where revenue grew 13.1%, a sharp acceleration from the 1.5% growth MiniMed posted in the prior quarter. The MiniMed Flex insulin pump, which began shipping in late June, is doing more than adding a new SKU. New pumps sold in the US climbed more than 20% year over year, and new prescribers writing for Flex rose 24%. Management said competitive conversions from rival pump makers have doubled since the launch, meaning MiniMed isn’t just capturing new patients starting therapy; it’s pulling existing users away from other systems.
International markets backed up the story. Revenue there grew 16.9%, powered by a threefold increase in Simplera sensor manufacturing output that let MiniMed finally meet demand in Western Europe. New pump sales jumped 50% in the UK and 20% in France after the region got access to the 15-day Instinct sensor. Roughly 40% of new US patient starts are now coming from Type 2 diabetics, a population MiniMed considers largely untapped, and CGM attachment on new pumps reached 69%, up from 64% a year ago, which locks in recurring sensor and consumable revenue behind every pump sold.
The pipeline is arriving early rather than late. MiniMed filed its 510(k) for the Fit patch pump ahead of schedule and now expects a full launch by summer 2027. Enrollment finished early in the pivotal trial for Vivera, a closed-loop algorithm that in feasibility testing let Type 1 patients hit 74% time in range with no manual input at all. On the back of that momentum, MiniMed raised its full-year organic revenue growth guidance to roughly 10.5% from 10%.
The Bills Are Coming Due
Growth came with a real cost. Adjusted EBITDA margin landed at just 9.9%, and free cash flow was negative $90 million for the quarter. Of that cash burn, $111 million came from separation and standup costs tied to building MiniMed into an independent company, without which free cash flow would have actually been positive $21 million. That’s a meaningful gap between the business MiniMed will eventually be, and the one investors are funding right now.
Margins took hits from two other directions. The company pulled forward $8 million in spending to speed up the Fit filing and the Flex launch, and a currency remeasurement charge on its balance sheet cost another $12 million, together shaving about 230 basis points off EBITDA margin. Separately, the Simplera sensor carries a lower margin than MiniMed’s older sensors, and that product mix is weighing on gross margin even as manufacturing yields improve. And MiniMed still isn’t fully untethered from its former parent. Only 17 of the 160 transition service agreements with Medtronic have been exited, with most of the rest not expected to wrap up until sometime in calendar 2027.
Investors should also note that an extra week in MiniMed’s fiscal calendar added 4 to 6 percentage points to this quarter’s growth rate. Strip that out and organic growth was still solid, in the low double digits, but management itself flagged that reported growth will “normalize” in the next quarter once that calendar boost disappears.
Wall Street Still Isn’t Sure
Hedge fund ownership of MiniMed rose from 22 funds to 26 in the most recent quarter, a sign institutional interest is building rather than fading. That accumulation is happening alongside a short interest of 20.66% of float, a level that reflects a genuine bear camp rather than routine hedging. That combination, funds buying in while short sellers stay heavily positioned against the stock, points to a real disagreement over whether the Flex-driven growth story holds up once the extra week and pipeline pull-forwards roll off the comps.
What Happens Next Matters Most
MiniMed spent its first quarter as an independent company proving its new products work, and the results back that up. But strong top-line growth arrived next to negative free cash flow and a still-incomplete separation from Medtronic. For the bull case to play out, Fit and Vivera need to launch on the timelines management just moved up, and the US growth acceleration needs to survive the loss of the extra-week boost.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
